|
Re: Covid Therapeutics Tracker
|
1
|
Resverlogix Corp.
|
May 08, 2021 10:20AM
|
|
Re: Covid Therapeutics Tracker
|
2
|
Resverlogix Corp.
|
May 08, 2021 10:53AM
|
|
Re: Deal or no Deal?
|
6
|
Resverlogix Corp.
|
Jul 23, 2020 11:01AM
|
|
Re: Deloitte
|
6
|
Resverlogix Corp.
|
May 06, 2021 01:34PM
|
|
Re: Deloitte
|
1
|
Resverlogix Corp.
|
May 06, 2021 01:38PM
|
|
Re: Did you notice?
|
7
|
Resverlogix Corp.
|
May 26, 2022 10:58AM
|
|
Re: Expected Results
|
2
|
Resverlogix Corp.
|
Jan 22, 2022 06:42PM
|
|
Re: Expected Results
|
3
|
Resverlogix Corp.
|
Jan 23, 2022 10:07AM
|
|
Re: Expected Results
|
3
|
Resverlogix Corp.
|
Jan 23, 2022 01:33PM
|
|
Re: Expiring Warrants
|
2
|
Resverlogix Corp.
|
Jun 28, 2021 01:05PM
|
|
Re: Farxiga (SGLT2i) approved for CKD patients with AND without T2D
|
|
Resverlogix Corp.
|
May 03, 2021 02:19PM
|
|
Re: Farxiga (SGLT2i) approved for CKD patients with AND without T2D
|
2
|
Resverlogix Corp.
|
May 02, 2021 03:20PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
5
|
Resverlogix Corp.
|
Apr 05, 2022 11:28AM
|
|
Re: Finance
|
6
|
Resverlogix Corp.
|
Aug 06, 2020 04:32PM
|
|
Re: Financing-Move On
|
9
|
Resverlogix Corp.
|
May 05, 2021 01:17PM
|
|
Re: Financing-Move On
|
5
|
Resverlogix Corp.
|
May 05, 2021 04:31PM
|
|
Re: For Scientists - Nature article/study on epigenetic changes after kidney injury
|
6
|
Resverlogix Corp.
|
Jul 25, 2020 05:32PM
|
|
Re: Form 45-106F1 Report of Exempt Distribution Dec 13, 2021
|
5
|
Resverlogix Corp.
|
Dec 14, 2021 02:38PM
|
|
Re: Hepa Links up close to the max 10% in early trading
|
2
|
Resverlogix Corp.
|
Apr 30, 2024 02:34PM
|
|
Re: Investalot Welcome to the RVX board on Agoracom.com
|
2
|
Resverlogix Corp.
|
Jun 30, 2020 08:51PM
|
